Linked Life Data

11359533

Source:http://linkedlifedata.com/resource/pubmed/id/11359533

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2001-5-21
pubmed:abstractText
Recent studies have suggested that cannabinoids might initiate the consumption of other highly addictive substances, such as opiates. In this work, we show that acute administration of Delta9-tetrahydrocannabinol in mice facilitates the antinociceptive and antidepressant-like responses elicited by the endogenous enkephalins protected from their degradation by RB 101, a complete inhibitor of enkephalin catabolism. This emphasizes the existence of a physiological interaction between endogenous opioid and cannabinoid systems. Accordingly, Delta9-tetrahydrocannabinol increased the release of Met-enkephalin-like material in the nucleus accumbens of awake and freely moving rats measured by microdialysis. In addition, this cannabinoid agonist displaced the in vivo [3H]diprenorphine binding to opioid receptors in total mouse brain. The repetitive pretreatment during 3 weeks of Delta9-tetrahydrocannabinol in mice treated chronically with morphine significantly reduces the naloxone-induced withdrawal syndrome. However, this repetitive administration of Delta9-tetrahydrocannabinol did not modify or even decrease the rewarding responses produced by morphine in the place preference paradigm. Taken together, these behavioural and biochemical results demonstrate the existence of a direct link between endogenous opioid and cannabinoid systems. However, chronic use of high doses of cannabinoids does not seem to potentiate the psychic dependence to opioids.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0953-816X
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1816-24
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11359533-Analgesics, pubmed-meshheading:11359533-Animals, pubmed-meshheading:11359533-Binding, Competitive, pubmed-meshheading:11359533-Conditioning (Psychology), pubmed-meshheading:11359533-Diprenorphine, pubmed-meshheading:11359533-Disulfides, pubmed-meshheading:11359533-Drug Interactions, pubmed-meshheading:11359533-Enkephalin, Methionine, pubmed-meshheading:11359533-Extracellular Space, pubmed-meshheading:11359533-Male, pubmed-meshheading:11359533-Mice, pubmed-meshheading:11359533-Morphine, pubmed-meshheading:11359533-Motor Activity, pubmed-meshheading:11359533-Narcotic Antagonists, pubmed-meshheading:11359533-Narcotics, pubmed-meshheading:11359533-Neurons, pubmed-meshheading:11359533-Nociceptors, pubmed-meshheading:11359533-Nucleus Accumbens, pubmed-meshheading:11359533-Phenylalanine, pubmed-meshheading:11359533-Psychotropic Drugs, pubmed-meshheading:11359533-Reward, pubmed-meshheading:11359533-Substance Withdrawal Syndrome, pubmed-meshheading:11359533-Tetrahydrocannabinol, pubmed-meshheading:11359533-Tritium
pubmed:year
2001
pubmed:articleTitle
Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect.
pubmed:affiliation
Département de Pharmacochimie Moléculaire et Structurale, U266 INSERM, UMR 8600 CNRS, UFR des Sciences Pharmaceutiques et Biologiques, 4, Avenue de l'Observatoire, 75270 Paris Cedex 06, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't